For the quarter ending 2025-09-30, CVKD made $2,781,901 in revenue. -$2,685,705 in net income. Net profit margin of -96.54%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative expenses | 2,044,937 | 2,656,392 | ||
| Research and development expenses | 688,465 | 1,077,498 | ||
| Depreciation expense | 401 | 401 | ||
| Total operating expenses | 2,733,803 | 3,734,291 | ||
| Loss from operations | -2,733,803 | -3,734,291 | ||
| Interest and dividend income | 48,098 | 67,004 | ||
| Total other income | 48,098 | 67,004 | ||
| Net loss and comprehensive loss | -2,685,705 | -3,667,287 | ||
| Net loss per common share, basic (in dollars per share) | -1.31 | -1.87 | ||
| Net loss per common share, diluted (in dollars per share) | -1.31 | -1.87 | ||
| Weighted average number of common shares used in computing net loss per common share, basic (in shares) | 2,044,033 | 1,961,642 | ||
| Weighted average number of common shares used in computing net loss per common share, diluted (in shares) | 2,044,033 | 1,961,642 | ||
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)